Next generation oncology drug development: opportunities and challenges.
about
Predictive and prognostic molecular markers for cancer medicineStopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.Multiple gene dysfunctions lead to high cancer-susceptibility: evidences from a whole-exome sequencing study.A Time-Trend Economic Analysis of Cancer Drug Trials.Molecular profiling of childhood cancer: Biomarkers and novel therapiesIn vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells.Modeling NSCLC progression: recent advances and opportunities availableOncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapyMethodological and practical challenges for personalized cancer therapies.Thymidylate synthase inhibitors for non-small cell lung cancer.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A.The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells.Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.The possible use of inorganic phosphate in osteosarcoma therapy.Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.[Clinical and health economic challenges of personalized medicine].Uncovering early, lineage-dependent effects of TPMT genotype in adult acute lymphoblastic leukemia by minimal residual disease.
P2860
Q28743108-A5E8B722-BF72-4020-A054-601E4EFD1164Q34094103-024BF380-97D6-44E0-9A70-1F405C969DF9Q34177065-37A86BC6-E862-4388-86F9-3FCF9A1E13A9Q35154233-29FD9AB8-FCB3-4501-8E09-01E36179382BQ35264099-88C6A695-7483-45C1-964D-A9A8959A8B52Q35820527-F6640210-3B63-4BD5-800A-666C09690A4FQ36250783-39DA65BB-B5CB-460A-972A-42C206B4DBA6Q36747337-5DFD9005-F19D-4E05-8AE6-A80375B5C1ACQ36858560-6EE16CC9-E597-48C6-81E0-A47DF6AF70DFQ36910615-3E1D9F66-5805-4541-86B1-FAD649013A2CQ37295261-F4E67E69-A528-41CF-9A3A-AF1F65D93FADQ37848661-1DAC6326-4E54-4361-92C3-62F6D4A939ABQ37929783-06AE6D18-AD03-4CD0-B9A6-C670026A5F74Q38030053-67255B7E-0903-4A38-8981-BBC043083990Q38164843-F0B424F3-599F-49FB-A138-EF78CB233553Q38748123-D3EF8CF8-64B9-4C71-B93B-39317F65E547Q38837835-4F4E77D2-9C1F-4DDA-AEDF-7665C7E892A1Q39335691-73E812FE-753F-4642-8932-1710FB9273A9Q39463417-799DF6AC-2C67-4674-BDFC-7ED7BAD54ACFQ50422614-112C24C3-BA2A-4F39-B916-849356C2C0A0Q51440848-86C11714-1217-4C69-A326-F38B1409B96FQ52740762-1B187FDC-35BB-48DC-8987-08D2C52A6850Q52888617-1839B374-FA23-425E-974D-2024D9AAE857Q54290207-D69B86F7-2D26-44E9-9109-59F07A54CCC5
P2860
Next generation oncology drug development: opportunities and challenges.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Next generation oncology drug development: opportunities and challenges.
@en
Next generation oncology drug development: opportunities and challenges.
@nl
type
label
Next generation oncology drug development: opportunities and challenges.
@en
Next generation oncology drug development: opportunities and challenges.
@nl
prefLabel
Next generation oncology drug development: opportunities and challenges.
@en
Next generation oncology drug development: opportunities and challenges.
@nl
P2093
P1476
Next generation oncology drug development: opportunities and challenges.
@en
P2093
Giuseppe Giaccone
Martin E Gutierrez
Shivaani Kummar
P2888
P304
P356
10.1038/NRCLINONC.2009.38
P407
P577
2009-05-01T00:00:00Z
P6179
1024249456